Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, September 29, 2015

Status Update on MS Biomarkers

Article provided to us by:  Cherie C. Binns RN BS MSCN

This article speaks of the importance of spinal fluid markers as we have come to rely on them as well as other blood components that may help us determine if a person is likely to have an aggressive course of MS.

Sept 28, 2015

Biomarkers are needed in multiple sclerosis (MS) to help with early diagnosis, estimate prognosis, and monitor treatment response, and a few candidates look promising, researchers reported.

In a review of the literature, new B-cell-associated blood biomarkers may be useful for predicting conversion to MS, and new markers of axonal damage may help with prognosis, according to Charlotte Teunissen, PhD, of VU University Medical Center in Amsterdam, and colleagues. They reported their findings in Nature Reviews Neurology..

There's still a tremendous need for biomarkers of treatment response and predicting adverse events, especially with the rise of disease-modifying therapies, they added.
Researchers have long been investigating biomarkers for MS in blood and cerebrospinal fluid (CSF). It started with the discovery of CSF-specific IgG oligoclonal bands (OCBs), which turned out to be sensitive diagnostic markers of MS. The search for additional body fluid markers grew from there, the researchers said.

The need for those markers is growing with the increasing recognition of greater heterogeneity of the disease, as well as the rise of pharmaceuticals that would be well served by ways to monitor treatment response and predict adverse effects.

For their paper, Teunissen and colleagues focused on body fluid markers -- they did not review genetic markers -- that have been assessed in recent studies, from 2012 to 2015, and validated in at least two independent cohorts.

For early diagnosis, researchers are trying to predict who will convert from clinically isolated syndrome (CIS) to MS, and several new B-cell-associated candidate blood biomarkers have emerged.

Studies have suggested that B-cell attracting CDC motif chemokine 13 (CXCL13) mRNA has high potential as a prognostic biomarker for CIS conversion to MS -- although its lack of specificity impedes its use as a diagnostic marker for MS. Similarly, Chitinase-3-like protein 1 (CHI3L1) has been shown to be a prognostic marker of conversion, but it needs further replication as a marker for MS, the researchers said.
Since IgG OCBs are a well-established independent prognostic factor for conversion from CIS to MS, IgM OCBs have become a promising prognostic marker for conversion. Other humoral immunity markers being investigated include IgG directed against neurotropic viruses and immunoglobulin free light chains.

Continue Reading

MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here

No comments: